Beyfortus won FDA approval in July as a passive immunization for RSV-related lower respiratory tract disease in newborns and infants born during or entering their first RSV season, plus young kids ...

Beyfortus is not known to interact with other medications, herbs, supplements, foods, or alcohol. The manufacturer of Beyfortus didn’t look at interactions in studies of the drug.

BEYFORTUS is a long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in ...

The second trial included 1490 term and late-preterm infants, of which 994 received Beyfortus; 1.2% of infants on Beyfortus were infected with MA RSV LRTI vs 5.0% in the placebo group.

Children's Health FDA approves new drug Beyfortus to protect babies, toddlers from RSV RSV can result in ‘large number’ of emergency department, physician visits, FDA official says ...

Beyfortus, provided directly to newborns and infants as a single dose, offers rapid protection via an antibody to help prevent LRTD caused by RSV, without requiring activation of the immune system ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial ...

Beyfortus is supplied as a 50mg/0.5mL and 100mg/mL prefilled syringe. The product is expected to be available for the upcoming 2023-2024 RSV season.

BEYFORTUS administration can be timed to coincide with the RSV season. BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world.

Sanofi has tripled Beyfortus production and doubled manufacturing sites since its 2023 launch. PPI and Industrial Production drop Wednesday morning — see how Matt Maley is trading the reaction ...